ALT Altimmune Inc

Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.

Altimmune management will host a conference call and webcast with a slide presentation beginning at 8:30 am E.T. Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at The company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

Conference Call Information:

Date: Tuesday, September 28
Time: 8:30 am Eastern Time
Domestic Dial-in:(844) 615-6509
International Dial-in:(918) 922-3148
Conference ID:3792068
Webcast:

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit .

Follow @Altimmune, Inc. on

Follow @AltimmuneInc on

Investor and Media Contact:

Will Brown

Chief Financial Officer

Phone: 240-654-1450



EN
27/09/2021

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Leerink Global Healthcare Conference Monday, March 9, 2026 – One-on-one meetingsWednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET Citizens Life Sciences Conference Tuesday, March 10, 2026 – One-on-one meetings Fireside cha...

4h / 14m 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Result...

Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Closing of $75 Million Registered Direct Offering ...

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. Th...

January 29, 2026 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces Pricing of $75 Million Registered Direct Offering ...

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross procee...

January 28, 2026 1 EN
Free Trial
ALT ALTIMMUNE INC

Altimmune Inc: 1 director

A director at Altimmune Inc bought 5,000 shares at 4.082USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...

01/09/26 January 9, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch